scispace - formally typeset
J

John A. Zaia

Researcher at City of Hope National Medical Center

Publications -  209
Citations -  11560

John A. Zaia is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Human cytomegalovirus. The author has an hindex of 53, co-authored 198 publications receiving 11145 citations. Previous affiliations of John A. Zaia include Massachusetts Department of Public Health & Harvard University.

Papers
More filters
Journal ArticleDOI

Ribozymes as potential anti-HIV-1 therapeutic agents.

TL;DR: The present study shows precise cleavage of human immunodeficiency virus type 1 (HIV-1) sequences in a cell-free system by hammerhead ribozymes, suggesting the feasibility of developing Ribozymes as therapeutic agents against human pathogens such as HIV-1.
Journal ArticleDOI

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

TL;DR: A controlled trial of ganciclovir in recipients of bone marrow transplants who had asymptomatic pulmonary CMV infection and sought to identify risk factors for the development of CMV interstitial pneumonia.
Journal ArticleDOI

Towards an HIV cure: a global scientific strategy

TL;DR: The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure and several priorities for basic, translational and clinical research were identified.
Journal ArticleDOI

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

TL;DR: Primary CMV infection via blood transfusion can be reduced by the provision of seronegative or leukocyte-depleted blood products, and indirect immunomodulatory effects of CMV are increasingly recognized in hematopoietic stem cell transplant recipients.
Journal ArticleDOI

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

TL;DR: The observation that CMV‐specific CTL can be induced in vitro using peptide fragments derived from pp65 supports the future use and manipulation of this and similar effector populations in a clinical setting.